Elekta AB/Skr EKTA B
1D1W1MYTD1Y5YMAX
Capital at risk
About Elekta AB
Elekta AB is a Swedish company specializing in the development and production of medical technologies used in radiotherapy and radiosurgery for treating cancer and brain disorders. Founded in 1972 and headquartered in Stockholm, Sweden, Elekta offers a range of products including linear accelerators, brachytherapy solutions, and software for treatment planning and digital health records management. The company is recognized for its emphasis on precision and efficiency in treatment delivery. Elekta operates globally, serving hospitals and cancer care centers across multiple continents, leveraging technological innovations to improve patient outcomes and workflow efficiency in healthcare facilities. Its strategic focus includes the continuous advancement of image-guided radiation therapy technologies.
- Ticker
- Skr EKTA B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 3,996
- Headquarters
- Stockholm, Sweden
- Website
- www.elekta.com
Elekta AB Metrics
BasicAdvanced
kr 21B
-
-kr 0.95
0.97
kr 2.40
4.62%
Price and volume
Market cap
kr 21B
Beta
0.97
52-week high
kr 66.70
52-week low
kr 41.86
Average daily volume
1.3M
Dividend rate
kr 2.40
Financial strength
Current ratio
0.864
Quick ratio
0.621
Long term debt to equity
0.542
Total debt to equity
0.898
Interest coverage (TTM)
5.93%
Profitability
EBITDA (TTM)
1,844
Gross margin (TTM)
39.60%
Net profit margin (TTM)
-2.18%
Operating margin (TTM)
9.22%
Effective tax rate (TTM)
648.48%
Revenue per employee (TTM)
kr 4,160,000
Management effectiveness
Return on assets (TTM)
3.43%
Return on equity (TTM)
-4.33%
Valuation
Price to revenue (TTM)
1.196
Price to book
2.74
Price to tangible book (TTM)
-6.01
Price to free cash flow (TTM)
12.86
Free cash flow yield (TTM)
7.78%
Free cash flow per share (TTM)
4.044
Dividend yield (TTM)
4.62%
Growth
Revenue change (TTM)
-6.89%
Earnings per share change (TTM)
-232.52%
3-year revenue growth (CAGR)
-1.48%
10-year revenue growth (CAGR)
4.34%
3-year earnings per share growth (CAGR)
-31.29%
10-year earnings per share growth (CAGR)
6.01%
10-year dividend per share growth (CAGR)
16.98%
Bulls say / Bears say
Adjusted gross margin expanded by 560 bps to 42.6% in Q1 FY26/27—driven by favorable product mix, price increases and a SEK 53 M US tariff refund—demonstrating strong margin leverage (Investing.com)
Order intake grew 3% with a book-to-bill ratio of 1.11 (vs. 1.05), primarily driven by strong demand for the Elekta Evo platform and Elekta ONE software, indicating a healthy future revenue pipeline (Investing.com)
At its June 17 Capital Markets Day, Elekta set mid-term targets of mid-single digit constant-currency sales CAGR, a 14–16% adjusted EBIT margin by FY28/29 and ~10% free cash flow margin, reinforcing management’s commitment to profitable growth (Elekta IR)
Q1 FY26/27 net sales declined 2% in constant currency (3% reported) to SEK 3,536 M as decreases in APJ and TIMEA offset gains in Americas and Europe, underscoring persistent top-line pressures (Investing.com)
Free cash flow before dividend and M&A remained negative at SEK –266 M in Q1, highlighting ongoing cash consumption despite improvements in earnings and lower R&D spend (Investing.com)
Sales in China fell 16% in constant currency in Q1, reflecting continued weakness in that key market and casting doubt on the timing of a meaningful recovery (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
Upcoming events
Funds containing Elekta AB
AllUSDEURGBP
Fund name | Fund size | Skr EKTA B weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.20% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.20% |
iShares Healthcare Innovation£DRDR | £1B | 0.20% |
iShares Ageing Population€AGED | €822M | 0.16% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.